TIDES USA 2024: Meet us in Boston

Join our team at TIDES USA 2024 to discuss your challenges in oligonucleotide, mRNA or peptide development. Learn from our experts leading strategies for expediting R&D and improving CMC efficiency. Meet our team at our stand #625.

Hybrid Event (in-person and digital) 
Where: Boston, MA, USA
When: May 14-17, 2024

To arrange a meeting, please email us: oligos@intertek.com

Oligonucleotide CMC Analytical Developments
Learn more about CMC analytical strategies for both drug substance and drug product to accelerate oligonucleotide product development. Learn More:

• Report: Analytical Challenges of Oligonucleotide Development
• White Paper: Analytical Strategies for Quality Control of Oligonucleotide Therapeutics  

Peptide Analytical and Formulation Development
Overcome challenges in product development and quality control through tailored QC analytical strategies - learn more:

• Report: Peptide Therapeutics - Designing a Science-Led Strategic Quality Control Program

mRNA Therapeutics/Vaccines Analytical Development
Learn more about CMC analytical approaches for mRNA therapeutics and vaccines from experts, and learn about advanced analytical approaches:

• On-Demand Webinar | CMC Considerations for mRNA Based Therapeutics 
  
  

Inhaled and Intranasal Drug Delivery Innovation
The delivery of oligonucleotides, peptides, mRNA therapeutics the targeted delivery approaches including orally inhaled and intranasal delivery. Learn more: 

• On-Demand Webinar: Development Strategies for Inhaled and Nasal Oligonucleotide and mRNA Products

Learn more about the event: TIDES USA 2024

Intertek's capabilities supporting CMC, manufacturing and commercialization of oligos, peptides or mRNA therapeutics and vaccines

For nearly 30 years we have helped the world’s most innovative pharmaceutical and biopharmaceutical companies to navigate the challenges of new product development, drug delivery, production and market release. We provide a broad range of cGMP, GLP, GCP laboratory services, with a focus on support for the development and production of mRNA, oligos, peptides, biologics or vaccines. We are adept in establishing GMP validated analytical methods including mRNA specific methods such as integrity, potency, capping efficiency, residual DNA template, residual dsRNA and delivery system testing (e.g. lipid nanoparticles (LNPs)). These comprehensive characterisation services provide data to determine protein expression and product purity, which can be directly linked to translation efficiency and immunogenicity. We also provide ICH stability and formulation development programs and have leading expertise for inhaled and nasal drug product development.

Oligonucleotide analysis | Oligonucleotide characterisation
mRNA characterisation and analysis | Peptide analysis and formulation
Development and validation | Physico-chemical characterisation
Cell based potency assays | Purity determination and impurity analysis
Aggregation analysis | Bioanalysis